Ailawadhi, S
Mikhael, J R
LaPlant, B R
Laumann, K M
Kumar, S http://orcid.org/0000-0001-5392-9284
Roy, V
Dingli, D
Bergsagel, P L
Buadi, F K
Rajkumar, S V
Fonseca, R
Gertz, M A
Kapoor, P
Sher, T
Hayman, S R
Stewart, A K
Dispenzieri, A
Kyle, R A
Gonsalves, W I
Reeder, C B
Lin, Y
Go, R S
Leung, N
Kourelis, T
Lust, J A
Russell, S J
Chanan-Khan, A A
Lacy, M Q
Article History
Received: 9 February 2017
Revised: 7 June 2017
Accepted: 5 July 2017
First Online: 1 September 2017
Competing interests
: SA has served on advisory board for Amgen, Novartis, Takeda and Pharmacyclics, and receives research funding from Pharmacyclics; JRM receives research funding from Abbvie, Celgene and Sanofi; SK receives research funding from Takeda, Celgene, Novartis, Abbvie, Janssen and Roche; DD receives research funding from Karyopharm, Amgen and Takeda; PLB receives research funding from Novartis, Constellation and Mundipharma, and has served on advisory board for Incyte, Janssen, Adaptive Bioscience and Juno Therapeutics; MAG receives research funding from Celgene, Janssen, Prothena, Ionis, Alnylam and Sandoz; PK has served on advisory board for Sanofi-Genzyme and receives research funding from Takeda, Celgene and Amgen; AKS receives research funding from Celgene, Amgen, Bristol Myers Squibb and Janssen; AD receives research funding from Celgene, Millennium, Pfizer and Janssen, and has received travel grant from Pfizer and Prothena; CBR receives research funding from Celgene, Novartis, Takeda and BMS; YL receives research funding from Janssen; ACK receives research funding from Pharmacyclics; MQL receives research funding from Celgene. The remaining authors declare no conflict of interest. Funding from CA 186781 was utilized to support investigator effort in data analysis and manuscript preparation for this trial.